Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 395Neoplasms 350Carcinoma, Non-Small-Cell Lung 313Prostatic Neoplasms 264Colorectal Neoplasms 236Lung Neoplasms 204Multiple Myeloma 163Pancreatic Neoplasms 147Ovarian Neoplasms 146Neoplasm Metastasis 141Leukemia, Myeloid, Acute 138Melanoma 118Squamous Cell Carcinoma of Head and Neck 100Carcinoma, Renal Cell 93Stomach Neoplasms 92Recurrence 92Lymphoma 91Lymphoma, Non-Hodgkin 89Endometrial Neoplasms 89Carcinoma, Hepatocellular 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 87Glioblastoma 85Brain Neoplasms 84Head and Neck Neoplasms 77Glioma 76Uterine Cervical Neoplasms 75Urinary Bladder Neoplasms 72Sarcoma 70Leukemia, Lymphocytic, Chronic, B-Cell 70Hematologic Neoplasms 68

Interventions

ebselen 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hearing Loss × 30 days × Clear all
NCT04915183 2026-06-05

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

NCT07407582 2026-06-05

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

University of Arizona

Phase 1/2 Recruiting
25 enrolled
GenitourinaryHead & Neck

Head and Neck Neoplasms, Neoplasms, Testicular Neoplasms, Hearing Loss

NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT07622407 2026-06-03

TIMELY REHAB

VA Office of Research and Development

Phase NA Not yet recruiting
74 enrolled
Head & Neck

Ototoxicity, Deglutition Disorders, Head and Neck Neoplasms, Hearing Loss, Sensorineural, Tinnitus, Hearing Loss, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡